AMAG, Allos to merge – but will it really bring sales synergies for Feraheme, Folotyn?
This article was originally published in Scrip
Executive Summary
AMAG Pharmaceuticals said it plans to merge with Allos Therapeutics in an all-stock deal in order to save money and leverage the sales efforts of the two companies, both of which have launched lead products with disappointing US sales. Both firms need to reach a wider audience to deliver for shareholders.